Bio-rad Laboratories Inc (BIO) Q2 2017 10-Q Quarterly Earnings

Short answer

Bio-rad Laboratories Inc (BIO) filed its Q2 2017 10-Q quarterly report on Aug 7, 2017 for the quarter ended Jun 30, 2017.

AI summary of MD&A and risk factor updates

Q2 revenue $504.7M, down 2.3% YoY from $516.8M, pressured by Western Europe ERP deployment
Net income margin 1.0% vs 3.5% YoY, gross margin 54.2% vs 54.2%
Best segment Life Science revenue $179.4M, down 0.3%; worst Clinical Diagnostics $322.1M, down 3.5%
Operating cash flow $6.2M vs $69.7M; capital expenditures $65.0M through six months
Cash, equivalents and short-term investments $712.9M; ERP transition and government spending constraints remained headwinds

New regulatory risk: European Parliament approved stricter in-vitro diagnostic and medical-device rules in April 2017
Most material operational update: Western Europe ERP deployment caused vendor-payment delays, product shortages, and lower productivity in second-quarter 2017
International compliance exposure: foreign subsidiaries generated 61% of net sales, increasing exposure to complex anti-corruption and privacy laws
Competitive market pressure: multi-year public tenders reduced participation opportunities and intensified competitor pricing
Financial risk: $434.9 million outstanding indebtedness and $200.0 million revolving facility, with $0.5 million used for standby letters of credit

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Compare quarters, check guidance or see what insiders and funds did around the report.